48th REITOX Heads of Focal Points (HFP)
Agenda item: RTX/48/01a Draft AGENDA (version 14-05-2013)
Thursday, 23 May 2013 Meeting place: EMCDDA former building Rua da Cruz de Santa Apolónia, 23-25 1149-045 Lisbon
09:00 - 10:30 1. Plenary session I: Introduction and welcome address (30 min.) a. Adoption of draft conclusions previous meeting (November 2012) b. Follow-up of decisions taken during previous meeting c. Report from the pre-Reitox meeting by the Reitox Spokesperson d. Adoption of final agenda
2. Plenary session II: Drug Supply Indicators – state of progress and way forward (1 hour) a. General overview of the Drug Supply Indicators, perspectives and link with work and role of Focal Points, Mr Roumen Sedefov, Head of unit, Ms Chloé Carpentier, Head of sector, EMCDDA c. Open discussion d. Next steps
10:30 - 11:00 Coffee break
11:00 - 12:30
3. Parallel session I: EMCDDA WP 2013 – work in progress (1 1/2 hour) a. Quality assurance: objectives and activities of the new Cross-Units Project (CUP) on Quality assurance, discussion of a case study: questions around expert ratings Introduction: Ms. Sandrine Sleiman, Quality assurance and scientific officer, EMCDDA Moderators: Mr Tim Pfeiffer-Gerschel, Reitox Spokesperson
b. Assessment of the 5 Key Indicators meetings: conclusions and perspectives Introduction: Mr Paul Griffiths, Scientific Director, EMCDDA Moderators: Mr Artur Malczewski, Reitox Deputy Spokesperson
c. Open discussion State of progress provides with short overview ongoing developments Oral introduction 10 minutes per area, with supporting room documents, no PowerPoints Two parallel sessions, will not be repeated – NFPs to prepare their questions/positions in pre- Reitox meeting
12:30 - 14:00 Lunch break
14:00 - 15:30 4. Parallel sessions II: Systemic Review of Tools – New developments (1 1/2 hour) a. Revision reporting tools on Treatment, Harm Reduction, Social reintegration, and analysis overlap and complementarity reporting tools and country profiles Introduction: Ms Dagmar Hedrich, Head of sector Moderators: Ms Maud Pousset, Head of French Focal Point
1 b. Best practice promotion project: conclusions January meeting and way forward with NFPs Introduction: Ms Marica Ferri; Scientific analyst Moderators: Mr Brian Galvin, Head of Irish Focal Point
State of progress provides with short overview ongoing developments Oral introduction 10 minutes per area, with supporting room documents, no PowerPoints Two parallel sessions, will not be repeated – NFPs to prepare their questions/positions in pre- Reitox meeting
15:30 - 16:00 Coffee break
16:00 - 17:30 5. Plenary session III: EMCDDA WP 2013 and Systemic Review (1 1/2 hour) a. Feedback parallel sessions, b. Conclusions and next steps
Friday, 24 May 2013 Meeting place: EMCDDA former building Rua da Cruz de Santa Apolónia, 23-25 1149-045 Lisbon
09:00 - 10:00 6. Plenary session IV: Reitox Accreditation System a. State of progress and feedback from the technical meeting of 6-7 March 2013, M. Alexis Goosdeel, Head of unit, EMCDDA b. Open discussion c. Conclusions and way forward
10:00 - 11:00 7. Plenary session V: Project Factory a. State of progress horizontal cooperation projects: Mr Ernestas Jasaitis, Head of Lithuanian Focal Point, Mr Artur Malczewski, Head of Polish Focal Point, Mr Viktor Mravcik, Head of Czech Focal Point, Ms Elisabetta Simeoni, Head of the Italian Focal Point. b. State of progress IPA and preparation ENP projects: Ms Cécile Martel, Head of sector and Mr Frédéric Denecker, Programme management officer, EMCDDA c. Open discussion d. Conclusions and way forward
11:00 - 11:45 8. Plenary session VI: “Research Forum” information on research and other EU programmes a. State of progress projects managed by or with participation of National Focal Points: Ms Maud Pousset, Head of the French Focal Point b. Research priorities EU-funded research programmes, Ms Maria Moreira, Drug- related research information officer, EMCDDA c. Open discussion d. Conclusions and way forward
11:45 - 12:00 9. Summary & conclusion
2